Monash University
Browse
Monash_Thesis_20220507_submission.pdf (11.92 MB)

Investigation of NPM1 mutation measurable residual disease (MRD) in acute myeloid leukaemia (AML) for early detection of relapse to guide pre-emptive therapy

Download (11.92 MB)
thesis
posted on 2022-07-05, 23:17 authored by ING SOO TIONG

Outcome of acute myeloid leukaemia (AML, an aggressive blood cancer) after disease recurrence (“relapse”) is very poor. This thesis examines the use of sensitive marker (measurable residual disease, MRD) to detect early signs of returning AML before relapses in a subgroup of AML with NPM1 mutations (leukaemia associated DNA changes). Venetoclax is a new treatment recently approved to target the “BCL2” (cancer survival pathway). I showed that early NPM1 MRD-guided treatment before relapse, using venetoclax plus low dose cytarabine (chemotherapy), is highly effective and tolerable, and could become the new treatment approach in relapsing AML.

History

Principal supervisor

Andrew Wei

Additional supervisor 1

David Curtis

Year of Award

2022

Department, School or Centre

Australian Centre for Blood Diseases

Additional Institution or Organisation

Clinical Haematology

Campus location

Australia

Course

Master of Philosophy

Degree Type

MASTERS

Faculty

Faculty of Medicine, Nursing and Health Sciences

Usage metrics

    Faculty of Medicine, Nursing and Health Sciences Theses

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC